RESUMEN
Subject of this study is an investigation of the variations of indoor radon concentration and ambient dose equivalent rate in outdoor and indoor environments of 40 dwellings, 31 elementary schools and five kindergartens. The buildings are located in three municipalities of two, geologically different, areas of the Republic of Macedonia. Indoor radon concentrations were measured by nuclear track detectors, deployed in the most occupied room of the building, between June 2013 and May 2014. During the deploying campaign, indoor and outdoor ambient dose equivalent rates were measured simultaneously at the same location. It appeared that the measured values varied from 22 to 990 Bq/m(3) for indoor radon concentrations, from 50 to 195 nSv/h for outdoor ambient dose equivalent rates, and from 38 to 184 nSv/h for indoor ambient dose equivalent rates. The geometric mean value of indoor to outdoor ambient dose equivalent rates was found to be 0.88, i.e. the outdoor ambient dose equivalent rates were on average higher than the indoor ambient dose equivalent rates. All measured can reasonably well be described by log-normal distributions. A detailed statistical analysis of factors which influence the measured quantities is reported.
Asunto(s)
Contaminación del Aire Interior/análisis , Ambiente , Monitoreo de Radiación , Radón/análisis , Análisis de Varianza , Análisis de Componente PrincipalRESUMEN
INTRODUCTION: New (188)Re and (99m)Tc peptide conjugates with substance- P (SP) were prepared and biologically evaluated. The radiopharmaceuticals have been labelled with the [M≡N](2+) (M=(99m)Tc, (188)Re) core using a combination of π-donor tridentate and π-acceptor monodentate ancillary ligands. METHODS: The new radiopharmaceuticals have been prepared through a two-step reaction by simultaneous addition of the tridentate and monodentate ligands to a vial containing a preformed [M≡N](2+) core. The tridentate ligand was formed by linking two cysteine residues to the terminal arginine of the undecapeptide SP, whereas the monodentate ligand was a tertiary phosphine. The preparation of the corresponding Re-188 derivative required developing a more complex chemical procedure to obtain the [Re≡N](2+) core in satisfactory yields. Characterization of the resulting products was obtained by chromatographic methods. Biological evaluation was performed for both Tc-99m and Re-188 derivatives by in-vitro studies on isolated cells expressing NK1-receptors. In-vivo imaging in mice was carried out using a small-animal YAP(S)PET tomograph. CONCLUSION: New Tc-99m and Re-188 peptide radiopharmaceuticals with SP have been prepared in high-yield and with high-specific activity. Both Tc-99m and Re-188 peptide radioconjugates exhibit high affinity for NK1 receptors, thus giving further evidence to the empirical rule that structurally related Tc-99m and Re-188 radiopharmaceuticals exhibit identical biological properties.
Asunto(s)
Neoplasias Experimentales/metabolismo , Radioisótopos/farmacocinética , Renio/química , Renio/farmacocinética , Sustancia P/farmacocinética , Tecnecio/química , Tecnecio/farmacocinética , Animales , Línea Celular Tumoral , Estabilidad de Medicamentos , Marcaje Isotópico/métodos , Tasa de Depuración Metabólica , Ratones , Neoplasias Experimentales/diagnóstico por imagen , Especificidad de Órganos , Radioisótopos/química , Radiofármacos/síntesis química , Radiofármacos/farmacocinética , Ratas , Sustancia P/química , Distribución Tisular , Tomografía Computarizada de Emisión de Fotón Único/métodosRESUMEN
Biodistribution studies of radiolabelled 131I-BSA loaded gelatin microspheres were carried out on BALB/c mice after peroral administration. To two groups, radiolabelled 131I-BSA gelatin microspheres of different particle size, 1.2 +/- 1.1 microm and 7.0 +/- 1.2 microm, were administered orally. To the control group, a solution of 131I-BSA was administered orally as well. Biodistribution was followed periodically within 15 days as the percent of total radioactivity present in the stomach and small intestine with Peyer's patches and mesentery, in colon with Peyer's patches, appendix and mesentery, in liver, spleen, blood, kidney, lungs and heart. Preliminary in vitro biodegradation and drug release studies confirmed the potential of gelatin microspheres to protect the antigen of interest from enzymatic degradation in the gut, and to release it in a controlled manner. The biodistribution data confirmed that particle uptake into Peyer's patches and passage to the liver and spleen via the mesentery lymph supply and nodes increased with decreasing particle size.